EHTH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
eHealth Inc (EHTH) is not a good buy for a beginner investor with a long-term strategy at this time. Despite a recent price increase, the stock faces significant challenges, including declining analyst ratings, reduced revenue guidance, and hedge fund selling. The technical indicators also suggest the stock is overbought, and there are no strong proprietary trading signals or positive catalysts to support a buy decision.
The MACD is positive and expanding, indicating bullish momentum. However, the RSI is at 82.377, signaling an overbought condition. The stock is trading near its resistance level of 1.851, suggesting limited upside potential in the short term.
The company's Q4 2025 revenue increased by 3.51% YoY, and gross margin improved slightly by 0.57%.
Analysts have significantly lowered price targets, citing weak revenue guidance and challenges in the Medicare Advantage market. Hedge funds are aggressively selling, with a 1442.15% increase in selling activity last quarter. Additionally, the stock is overbought based on RSI, and there are no recent news or congress trading data to provide a positive sentiment boost.
In Q4 2025, revenue grew by 3.51% YoY to $326.2M. However, net income dropped by 13.72% YoY to $73.93M, and EPS fell by 17.01% YoY to 2.39. This indicates declining profitability despite slight revenue growth.
Recent analyst actions are overwhelmingly negative. RBC Capital, Deutsche Bank, and Craig-Hallum have all lowered price targets significantly, with the highest target now at $3. Analysts cite weak revenue guidance and a challenging market environment as key concerns.
